Back to Journals » OncoTargets and Therapy » Volume 14

Long Noncoding RNA RGMB-AS1 Acts as a microRNA-574 Sponge Thereby Enhancing the Aggressiveness of Gastric Cancer via HDAC4 Upregulation [Retraction]

Authors Wang X, Chen X, Tian Y, Jiang D, Song Y

Received 13 July 2021

Accepted for publication 13 July 2021

Published 22 July 2021 Volume 2021:14 Pages 4267—4268

DOI https://doi.org/10.2147/OTT.S329199



Wang X, Chen X, Tian Y, Jiang D, Song Y. Onco Targets Ther. 2020;13:1691–1704.

The Editor-in-chief and Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were raised of alleged image duplication occurring in flow cytometry images found within the article and across other publications for unrelated studies. Specifically:

  • Figure 2C panel AGS si-RGMB-AS1, Figure 4C panel MGC-803 agomir-574 and Figure 6B panel MGC-803 si-RGMB-AS1+antagomir-NC all share an acceptable level of similarity to each other and images found in:

The authors responded to our queries but were unable to provide a satisfactory explanation for the alleged duplication or provide raw data for the flow cytometry experiments. It was determined the findings of the study could not be supported and the decision was made to retract the article. The authors agree with this decision.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

This retraction relates to this paper

Creative Commons License © 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.